Daunorubicin attenuates tumor necrosis factor-α-induced biosynthesis of plasminogen activator inhibitor-1 in human umbilical vein endothelial cells  by Soeda, Shinji et al.
Daunorubicin attenuates tumor necrosis factor-K-induced biosynthesis of
plasminogen activator inhibitor-1 in
human umbilical vein endothelial cells
Shinji Soeda, Kenji Iwata, Yoshiko Hosoda, Hiroshi Shimeno *
Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku,
Fukuoka 814-0180, Japan
Received 4 October 2000; received in revised form 15 January 2001; accepted 16 January 2001
Abstract
The anthracycline antibiotic daunorubicin is reported to induce apoptosis in cells by triggering ceramide generation
through de novo synthesis or sphingomyelin hydrolysis. Treatment of human umbilical vein endothelial cells (HUVEC) with
daunorubicin markedly decreased the mRNA expression and protein release of plasminogen activator inhibitor-1 (PAI-1).
This cellular event was accompanied by a significant increase in the total ceramide content in HUVEC. On the other hand,
tumor necrosis factor (TNF)-K treatment of HUVEC led to an increase in both PAI-1 mRNA expression and protein release,
and an enhancement of total ceramide content was also observed. The stimulating effect of TNF-K on PAI-1 synthesis was
attenuated by the pretreatment of HUVEC with daunorubicin. Interestingly, the daunorubicin-induced increase in ceramide
content was blocked by addition of the potent ceramide synthase inhibitor fumonisin B1, while the TNF-K-induced ceramide
increase was not affected by this drug. Fumonisin B1 treatment restored the daunorubicin-induced decrease in PAI-1 release
to approximately 70% of the control, but did not affect the TNF-K-induced increase in PAI-1 release. Thus, these data imply
the possibility that the subcellular topology of ceramide production determines its lipid mediator function in the regulation of
PAI-1 synthesis in HUVEC, because both TNF-K and daunorubicin could increase the ceramide levels. ß 2001 Elsevier
Science B.V. All rights reserved.
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1. Introduction
Plasminogen activator inhibitor-1 (PAI-1) is an
important physiological regulator of ¢brinolysis.
PAI-1 rapidly inactivates tissue-type and urokinase-
type plasminogen activators (PAs) and blocks the
generation of the ¢brinolytic enzyme plasmin. The
expression of PAI-1 is enhanced in atherosclerotic
plaques [1^3], and a linkage between an excess of
circulating [4] or arterial [5] PAI-1 and the risk of
intravascular thrombotic events has been reported.
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Macrophages, which are central cell types in athero-
sclerosis, produce large amounts of cytokines such as
interleukin 1 and tumor necrosis factor (TNF)-K.
TNF-K stimulates PAI-1 synthesis by various cell
types in vitro and in vivo [6^10]. However, the
TNF-K signaling events leading to PAI-1 production
are not yet fully understood.
We have recently demonstrated that TNF-K-in-
duced release of PAI-1 from human umbilical vein
endothelial cells (HUVEC) is accompanied by an el-
evation of intracellular ceramide levels, and sug-
gested an important role of the ceramide as the sig-
naling molecule [9]. TNF-K may activate the
sphingomyelin (SM) pathway located in the endoso-
mal/lysosomal compartments [9] and/or in the plas-
ma membrane [11], where the activated sphingomye-
linase (SMase) hydrolyzes SM to generate ceramide.
However, a recent report [12] suggests that the ele-
vation of de novo synthesis of ceramide is involved
in TNF-K signaling of cultured cerebral endothelial
cells. De novo ceramide synthesis occurs in micro-
somes via activation of ceramide synthase (EC
2.3.1.24) [13]. The anthracycline antibiotic daunoru-
bicin could activate this enzyme to induce apoptosis
in P388 and U937 cells [14]. This ¢nding has also
been challenged by Ja¡re¤zou et al. [15], where cer-
amide generation via SM hydrolysis underlies the
drug-triggered apoptosis in HL-60 and U937 cells.
The response of cells to daunorubicin may di¡er be-
tween various cell types and depend on the drug
concentration used. Additionally, how long the cells
are exposed to the drug may determine the ceramide
generation mechanism.
In the present study, to examine the e¡ect of dau-
norubicin on HUVEC, the cells were treated for
30 min with a high concentration (20 WM) of the
drug, washed out, and incubated in the culture me-
dium alone. These procedures may at least prevent
the injurious actions of daunorubicin on HUVEC.
We report that the incorporated daunorubicin sup-
presses the PAI-1 mRNA expression and protein
synthesis in HUVEC after an increase in cellular cer-
amide levels. We further show that TNF-K also in-
creases the ceramide levels in HUVEC but conversely
enhances the biosynthesis of PAI-1. The TNF-K-in-
duced increase in PAI-1 synthesis is attenuated by
daunorubicin pretreatment. Fumonisin B1 is a potent
and speci¢c inhibitor of ceramide synthase with no
obvious e¡ects on other enzymes of SM metabolism
[16]. This agent could restore the daunorubicin-in-
duced decrease in PAI-1, but did not a¡ect the
TNF-K-induced increase in PAI-1 release. Our
present data suggest that daunorubicin mainly uti-
lizes de novo synthesized ceramide for the down-reg-
ulation of PAI-1 gene expression in HUVEC. In con-
trast, TNF-K may trigger ceramide generation via
SM hydrolysis to up-regulate PAI-1 synthesis.
2. Materials and methods
2.1. Materials
The following reagents were commercially ob-
tained: daunorubicin, fumonisin B1, N-palmitoyl-D-
sphingosine (C16-ceramide) from Sigma; and re-
combinant human TNF-K (1.0U108 U/mg protein)
from Boehringer Mannheim.
2.2. Cell culture and treatment
Cryo HUVEC and the culture medium EGM-2
were purchased from Sanko Junyaku, Tokyo, Japan.
EGM-2 is composed of modi¢ed MCDB 131 me-
dium and supplements that contain fetal bovine se-
rum, epidermal growth factor, basic ¢broblast
growth factor, insulin-like growth factor, vascular
endothelial growth factor, heparin, ascorbic acid, hy-
drocortisone, amphotericin B and gentamicin. The
cells were grown in EGM-2 at 37‡C in a humidi¢ed
5% CO2 atmosphere. All experiments were per-
formed with HUVEC at passages 3^5. For experi-
ments, HUVEC were seeded in 6-well plates at a
density of 2.5U103 cells/cm2 and allowed to reach
con£uence in EGM-2. After removal of the condi-
tioned medium, the cell layer was rinsed twice with
GIT medium (Daigo Eiyo, Osaka, Japan), which is
serum-free but contains 3 mg/ml growth factors iso-
lated from bovine serum (corresponding to the addi-
tion of 10% fetal bovine serum), 2 Wg/ml insulin,
2 Wg/ml transferrin, 122 ng/ml ethanolamine, amino
acids, vitamins, and inorganic components. Prior to
the treatment with TNF-K, HUVEC were pretreated
at 37‡C for 30 min in 3 ml of GIT medium supple-
mented with the indicated agent and rinsed with GIT
medium. Incubation followed at 37‡C for a de¢nite
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time in 3 ml of GIT medium. Daunorubicin and
fumonisin B1 were dissolved in ethanol. Control cells
were treated with identical volumes of ethanol ve-
hicle.
2.3. Assay of PAI-1 antigen
Antigen levels of PAI-1 in the conditioned media
were determined with an enzyme-linked immuno-
sorbent assay (ELISA) kit, Imulyse PAI-1 (Biopool,
Umeafi, Sweden), according to the manufacturer’s in-
structions. This assay detects the free form of PAI-1,
but not the PA/PAI-1 complex.
2.4. Determination of total ceramide content
HUVEC were maintained in GIT medium at 37‡C
for a de¢nite time, after pretreatment for 30 min with
the indicated agent. The cells were detached, centri-
fuged, and washed with cold phosphate-bu¡ered sa-
line (PBS). The washed cells (1U106) were resus-
pended in 220 Wl of cold PBS. The cell suspension
was mixed with 4 ml of chloroform/methanol (2:1,
v/v) and extracted for 15 min. After the addition of
1 ml water, the sample was vortexed and centrifuged.
The lower layer was collected and evaporated to dry-
ness under a nitrogen stream. The amount of C16-
ceramide in the residue was quantitated by liquid
chromatography/ion spray ionization mass spectrom-
etry (LC/MS) according to the method described by
Mano et al. [17] with minor modi¢cations. Brie£y,
high-performance liquid chromatography (HPLC)
was performed using a Gulliver 1500 series HPLC
system (Jasco, Tokyo, Japan) equipped with a Devel-
osil ODS HG-5 reversed-phase column (35U2.0 mm
i.d., 5 Wm, Nomura Chemical, Aichi, Japan). The
mobile phases were as follows: A, 5 mM ammonium
formate/methanol/tetrahydrofuran (5/2/3, v/v); and
B, 5 mM ammonium formate/methanol/tetrahydro-
furan (1/2/7, v/v) containing 0.01% formic acid. Elu-
tion was performed at a £ow rate of 0.2 ml/min with
the following modi¢cation: 70% mobile phase A^
100% mobile phase B for 6.3 min in a linear gradient
mode. LC/MS analyses were done with an electro-
spray ionization mass spectrometer (Finnigan-LCQ)
and Navigator (Finnigan).
2.5. RNA extraction and RT-PCR analysis
Total RNA was isolated from either control or the
indicated agent-treated HUVEC, using an RNeasy
mini kit (Qiagen). The synthesis of ¢rst strand
cDNAs was performed with the Superscript system
(Gibco BRL), according to the manufacturer’s in-
structions. Oligonucleotide primers were prepared
as described by Hill et al. [18]. The PAI-1 forward
5P-CGGAGCACGGTCAAGCAAGTG-3P and PAI-
1 reverse 5P-GGTGAGGGCAGAGAGAGGCAC-3P
primers were used to amplify a 400-bp fragment near
the 3P end of the PAI-1 cDNA. Glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) forward 5P-C-
CCATGGCAAATTCCATGGCA-3P and reverse 5P-
TCTAGACGGCAGGTCAGGTCCACC-3P primers
were used to amplify a 600-bp fragment. Polymerase
chain reaction (PCR) ampli¢cation, using cDNA
from the reverse transcriptase (RT) reaction, was
performed with the PCR Reagent System (Gibco
BRL) in a Program temp.control system (PC-701,
Astec, Fukuoka, Japan). We selected a number of
25 cycles. PCR started for 2 min at 94‡C followed
by cycles consisting of: 60 s at 60‡C, 60 s at 72‡C,
and 60 s at 94‡C. Ampli¢cation was terminated after
7 min at 72‡C. Products were visualized and photo-
graphed under UV radiation following 1% agarose
gel electrophoresis.
3. Results
3.1. E¡ect of daunorubicin on PAI-1 expression in
HUVEC
We ¢rst tested the e¡ects of daunorubicin and fu-
monisin B1 which are the activator [14,15] and inhib-
itor [16], respectively, of ceramide generation, on
PAI-1 mRNA and protein levels in HUVEC. HU-
VEC were pretreated for 30 min with each agent,
rinsed, and incubated in the conditioned medium
alone. Daunorubicin dose-dependently decreased
the PAI-1 antigen levels in media as early as 6 h after
the treatment; the suppression lasted for at least 24 h
(Fig. 1A). This was in contrast to the e¡ect seen with
TNF-K [9], where the PAI-1 release was enhanced in
BBAMCR 14732 17-4-01
S. Soeda et al. / Biochimica et Biophysica Acta 1538 (2001) 234^241236
a time- and concentration-dependent manner. Fumo-
nisin B1 pretreatment did not a¡ect the PAI-1 anti-
gen levels (Fig. 1B). Fig. 2 shows that daunorubicin,
but not fumonisin B1, reduced the PAI-1 mRNA
levels slightly at 5 WM and clearly at 20 WM at 6 h
(PAI-1 mRNA at 6 h appears to be wiped out, but,
truly, a small amount of the mRNA is expressed at
that time. An increase in cycles of PCR could visual-
ize it). These daunorubicin e¡ects are expected to
have resulted from the increased intracellular ceram-
ide levels following the activation of ceramide syn-
thase [14] or SMase [15]. Therefore, we quantitated
the C16-ceramide content in these cells by LC/MS
analysis (Fig. 3). The pretreatment with 20 WM dau-
norubicin for 30 min and following incubation for
2 h in the conditioned medium alone increased the
ceramide content to 2.8-fold of the control
(61.5 þ 5.95 ng vs. 171 þ 8.57 ng, P6 0.001). Changes
in the ceramide content were not detected with fu-
Fig. 1. E¡ects of daunorubicin (A) and fumonisin B1 (B) on
the release of PAI-1 antigen from HUVEC. Con£uent HUVEC
in 6-well plates were pretreated for 30 min with daunorubicin
(Dau) or fumonisin (Fum) at the indicated concentrations,
rinsed, and incubated in serum-free GIT medium alone. PAI-1
levels in the media were measured at de¢nite times by ELISA.
Each bar represents the mean þ S.D. of three independent ex-
periments. *P6 0.05; ***P6 0.001, compared to control.
Fig. 2. Daunorubicin, but not fumonisin B1, selectively reduces
PAI-1 mRNA expression. HUVEC (1U106 cells) were pre-
treated for 30 min with daunorubicin (Dau) or fumonisin
(Fum) at the indicated concentrations, rinsed, and incubated
for 6 h in serum-free GIT medium alone. PAI-1 and GAPDH
mRNA levels were evaluated by RT-PCR as described in Sec-
tion 2. The ¢gure represents one of two independent experi-
ments that produced very similar results.
Fig. 3. Changes in ceramide content of HUVEC after treatment
with daunorubicin or fumonisin B1. HUVEC (1U106 cells)
were pretreated for 30 min with 20 WM daunorubicin (Dau) or
20 WM fumonisin (Fum), rinsed, and incubated for 2 h in se-
rum-free GIT medium alone. The cells were harvested and pro-
cessed for lipid extraction and C16-ceramide analysis by LC/MS
as described in Section 2. Each bar represents the mean þ S.D.
of three independent experiments. ***P6 0.001, compared to
control.
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monisin B1 treatment. Thus, the daunorubicin-in-
duced suppression of PAI-1 expression in HUVEC
may be closely related to primarily increased ceram-
ide (increase in antigen levels, 6^24 h; in mRNA
levels, 3^6 h; and in ceramide levels, 2 h). In con-
trast, fumonisin B1 pretreatment had little or no ef-
fect on the ceramide levels and PAI-1 expression.
One possible explanation for the lack of e¡ect of
fumonisin B1 may be that HUVEC do not operate
the ceramide synthase under these culture conditions
without the activator, daunorubicin. However, it re-
mains to be determined whether the daunorubicin-
induced increase in ceramide content is due to acti-
vation of ceramide synthase [14] or of SM hydrolysis
[15].
3.2. TNF-K-induced PAI-1 expression in HUVEC is
attenuated by daunorubicin
We previously investigated the biochemical mech-
anism of the TNF-K-induced release of PAI-1 from
HUVEC, and suggested that ceramide generation
underlay the induction of PAI-1 release [9]. We
next tested the e¡ect of daunorubicin on the TNF-
K-induced increase in PAI-1 synthesis. HUVEC were
pretreated with 1, 5, or 20 WM daunorubicin for
30 min, rinsed, and exposed to a saturated concen-
tration (500 U/ml) of TNF-K (Fig. 4A). After a 6-h
incubation of HUVEC with TNF-K alone, the PAI-1
antigen levels in media rose from 166 þ 25.0 to
311 þ 21.3 ng/ml (1.9-fold increase, compared to the
control). Pretreatment with daunorubicin caused a
suppression of the TNF-K-induced increase in PAI-
1 release: the concentration-dependent suppression
lasted for at least 24 h. Fig. 4B shows the expression
of PAI-1 and GAPDH mRNAs at 3 and 6 h. A 6-h
exposure of HUVEC to 500 U/ml TNF-K caused an
elevation of PAI-1 mRNA levels, compared to the
control. However, the TNF-K-induced increase in
PAI-1 mRNA levels was suppressed by daunorubicin
pretreatment in a concentration-dependent manner
(PAI-1 mRNA at 6 h appeared to be wiped out,
but, truly, a small amount of the mRNA is expressed
at that time. An increase in cycles of PCR could
visualize it).
We next determined the e¡ect of TNF-K on the
total ceramide content in HUVEC (Fig. 5A). After
a 2-h exposure of HUVEC to TNF-K (500 U/ml), the
ceramide content was increased to 156% of the con-
trol (79.4 þ 7.68 ng vs. 123 þ 8.36 ng, P6 0.001). Pre-
treatment of HUVEC with 20 WM fumonisin B1 did
not a¡ect the TNF-K-induced increase in ceramide
content (119 þ 13.1 ng). On the other hand, fumoni-
sin B1 (20 WM) reduced the daunorubicin-induced
increase in ceramide levels to near the control
(96.0 þ 14.9 ng). Additionally, daunorubicin plus
TNF-K treatment increased the total ceramide con-
tent, but there was no signi¢cant di¡erence between
the treatments with daunorubicin plus TNF-K and
daunorubicin alone. Daunorubicin treatment might
maximally elevate the ceramide levels in HUVEC.
Fig. 4. Daunorubicin suppresses the TNF-K-induced increase in
PAI-1 antigen (A) and PAI-1 mRNA (B) levels in a concentra-
tion-dependent manner. HUVEC (1U106 cells) were pretreated
for 30 min with 1^20 WM daunorubicin (Dau), rinsed, and ex-
posed to 500 U/ml TNF-K. (A) PAI-1 antigen levels in the con-
ditioned medium were measured by ELISA. Each bar represents
the mean þ S.D. of three independent experiments. *P6 0.05;
**P6 0.01; ***P6 0.001, compared to TNF-K alone. (B) PAI-
1 and GAPDH mRNA levels were evaluated by RT-PCR as
described in Section 2. The ¢gure represents one of three inde-
pendent experiments that produced very similar results.
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These data strongly suggest that TNF-K-induced cer-
amide is not the ceramide that resulted from dauno-
rubicin treatment. As shown in Fig. 5B, pretreatment
with fumonisin B1 did not a¡ect the TNF-K-induced
release of PAI-1, but restored the daunorubicin-in-
duced suppression of PAI-1 release to approximately
70% of the control. Therefore, these data suggest
that TNF-K signals to mainly generate ceramide via
SM hydrolysis and that, conversely, a large part of
the ceramide generated by daunorubicin is de novo
synthesized product. Furthermore, TNF-K- and dau-
norubicin-induced changes in PAI-1 biosynthesis re-
spond well to the increase in ceramide generation,
suggesting that, in both cases, the generated ceram-
ides act as the up- and down-regulators of PAI-1,
respectively.
4. Discussion
Daunorubicin has been proven to have therapeutic
bene¢t in the treatment of a variety of neoplasias.
However, its mechanism of anti-tumor action is not
yet fully understood, although DNA is believed to be
a primary target [19]. Recently, daunorubicin was
shown to increase ceramide levels in cells following
the induction of ceramide synthase [14] or of SM
hydrolysis by SMase [15]. Furthermore, inhibition
of ceramide synthase by the mycotoxin fumonisin
B1 blocks apoptosis induced by daunorubicin [14].
Multiple experimental data support the notion that
ceramide generated by SM hydrolysis plays an im-
portant role as the putative second messenger in reg-
ulating such diverse responses as cell cycle arrest,
apoptosis, and cell senescence [20], although the con-
cept has recently been challenged [21].
Here, we have shown that daunorubicin reduces
the expression and biosynthesis of PAI-1 in HUVEC.
PAI-1 mRNA decreased within 6 h in the cells, and
this decrease was re£ected in PAI-1 antigen levels up
to at least 24 h. The early increase in total ceramide
content (within 2 h) strongly suggests that ceramide
plays an important role in the suppression of PAI-1
biosynthesis. Fumonisin B1 (20 WM) treatment re-
stored the daunorubicin-induced decrease in PAI-1
antigen release to approximately 70% of the control.
The maximal restoration decreased with decreasing
concentrations of fumonisin B1. Treatment of HU-
VEC with 1 WM fumonisin B1 had no e¡ect, but with
5 WM the agent restored the reduction of PAI-1 re-
lease to 50% of the control (data not shown). These
results indicate that daunorubicin mainly induces the
activation of ceramide synthase in HUVEC within
Fig. 5. E¡ect of fumonisin B1 on the TNF-K-induced increase
in the total ceramide content (A) and in PAI-1 release from
HUVEC (B). HUVEC (1U106 cells) were pretreated for 30 min
with 20 WM daunorubicin (Dau) or 20 WM fumonisin (Fum) or
their combination, rinsed, and exposed to 500 U/ml TNF-K for
2 h. The cells were harvested and processed for lipid extraction
and C16-ceramide analysis by LC/MS and the media were pro-
cessed for determination of PAI-1 antigen as described in Sec-
tion 2. Each bar represents the mean þ S.D. of three independ-
ent experiments. ***P6 0.001, compared to control.
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2 h and that the generated ceramide may act as the
lipid messenger to reduce PAI synthesis and release.
However, the partial restoration of PAI-1 release by
fumonisin B1 treatment suggests that ceramide is
partly generated by SM hydrolysis, and how the cer-
amide regulates the PAI-1 synthesis remains obscure.
Recently, Ja¡re¤zou et al. [15] have shown that expo-
sure of HL-60 cells to 1 WM daunorubicin for 4^10
min and 60^70 min concomitantly increases ceramide
levels by neutral SMase, but not by ceramide syn-
thase. The authors suggest an important role of the
early SM-derived ceramide in daunorubicin-induced
apoptosis. Here, we determined the ceramide levels in
HUVEC at 2 h after the pretreatment procedures
with 20 WM daunorubicin. The exposure of HUVEC
for only 30 min to the high concentration of dauno-
rubicin may have greatly in£uenced the neutral
SMase present in plasma membranes. The time
course of decrease in PAI-1 expression following
the increase in ceramide levels seems to be convinc-
ing to explain the function of de novo synthesized
ceramide as the down-regulator of PAI-1 synthesis.
TNF-K also increased the ceramide content in
HUVEC within 2 h, but conversely enhanced the
biosynthesis of PAI-1. Additionally, the elevation
of ceramide at 2 h was not blocked by the ceramide
synthase inhibitor fumonisin B1. This result implies
that the TNF-K-induced ceramide is mainly caused
by SM breakdown, but not by de novo synthesis [12].
To date, seven di¡erent SMases have been found in
mammalian cells, tissues, and biological £uids [20].
Previously, we observed a signi¢cant elevation of
acidic lysosomal SMase activity in TNF-K-treated
HUVEC [9]. However, the acidic SMase gene gives
rise to both lysosomal SMase and secretory SMase,
which is fully or partially dependent on Zn2 for
enzyme activity [22]. Segui et al. [23] have recently
shown that TNF-K does not induce the generation of
ceramide by acidic SMase during apoptosis in cells.
At present, we have no data to bring forward to the
apoptotic role of acidic SMase and its product, cer-
amide. However, TNF-K increases PAI-1 biosynthe-
sis at least by increasing ceramide levels, which are
not de novo synthesized but are a SM breakdown
product. It is adequate to conclude that the increased
ceramide is due to SM hydrolysis by the other
SMase(s) or by the acid SMase gene product.
TNF-K increased both PAI-1 mRNA and PAI-1
antigen levels within 3 and 6 h, respectively. These
time course data strongly suggest that the ceramide
generated at 2 h is closely related to the e¡ect of
TNF-K on PAI-1 expression, but there is at present
no crucial evidence that ceramide is the signaling
molecule to regulate PAI-1 synthesis. Taken togeth-
er, our present ¢ndings suggest that, if ceramides
induced by daunorubicin and TNF-K act as the sig-
nal messenger, the subcellular topology of ceramide
production is important for determining the ceram-
ide signaling to regulate PAI-1 expression in HU-
VEC.
Finally, pathological roles of elevated PAI-1 levels
in coronary artery disease [1^5] and in a number of
tumors [24^26] have been reported. An interesting
role of PAI-1 on tumor cells has recently been sug-
gested: the bad prognostic factor, PAI-1, released
from tumor cells inhibits their apoptotic process
[27]. The present data that daunorubicin could de-
crease PAI-1 biosynthesis in HUVEC suggest a pos-
sible role of this drug as a down-regulator of PAI-1
expression in tumors. We treated HUVEC with
20 WM daunorubicin but removed the drug from
the cell culture after 30 min. The amount of dauno-
rubicin incorporated into the cells may be near to the
clinically achievable concentrations (6 5 WM). If the
drug were left in the cell culture, 2 WM daunorubicin
induces a similar decrease in PAI-1 release from HU-
VEC (data not shown). The suppressive e¡ects of
daunorubicin on PAI-1 synthesis may be an addi-
tional therapeutic bene¢t of this drug for cancers.
Acknowledgements
We gratefully acknowledge Mr. Hideyuki Yoshida,
Faculty of Pharmaceutical Sciences, Fukuoka Uni-
versity for technical instruction in LC/MS analysis.
This work was supported in part by a Grant-in-Aid
for Scienti¢c Research (C) from the Ministry of Ed-
ucation, Science, Sports and Culture of Japan and by
funds from the Central Research Institute of Fukuo-
ka University.
References
[1] J. Schneiderman, M.S. Sawdey, M.R. Keeton, G.M. Bordin,
BBAMCR 14732 17-4-01
S. Soeda et al. / Biochimica et Biophysica Acta 1538 (2001) 234^241240
E.F. Bernstein, R.B. Dilley, D.J. Lodkuto¡, Proc. Natl.
Acad. Sci. USA 89 (1992) 6998^7002.
[2] N. Chomiki, M. Henry, M.C. Alessi, F. Anfosso, I. Junhan-
Vague, Thromb. Haemost. 72 (1994) 44^53.
[3] L.A. Robbie, N.A. Booth, P.A.J. Brown, B. Benett, Arte-
rioscler. Thromb. Vasc. Biol. 16 (1996) 539^545.
[4] I. Juhan-Vague, S.D.M. Pyke, M.C. Alessi, J. Jespersen, F.
Haverkate, S.G. Thompson, Circulation 94 (1996) 2057^
2063.
[5] B.E. Sobel, J. Woodcock-Mitchell, D.J. Schneider, R.E.
Holt, K. Marutsuka, H. Gold, Circulation 97 (1998) 2213^
2221.
[6] V.W. van Hinsbergh, T. Kooistra, E.A. van den Berg, H.M.
Princen, W. Fiers, J.J. Emeis, Blood 72 (1988) 1467^1473.
[7] T. Kooistra, Fibrinolysis 4 (1990) 33^39.
[8] M. Sawdey, D.J. Loskuto¡, J. Clin. Invest. 88 (1991) 1346^
1353.
[9] S. Soeda, T. Tunoda, Y. Kurokawa, H. Shimeno, Biochim.
Biophys. Acta 1448 (1998) 37^45.
[10] S. Lopez, F. Peiretti, B. Bonardo, I. Juhan-Vague, G. Nal-
bone, J. Biol. Chem. 275 (2000) 3081^3087.
[11] L.M. Obeid, C.M. Linardic, L.A. Karolak, Y.A. Hannun,
Science 259 (1993) 1769^1771.
[12] J. Xu, J. Biol. Chem. 273 (1998) 16521^16526.
[13] A.H. Merrill Jr., D.D. Jones, Biochim. Biophys. Acta 1044
(1990) 1^12.
[14] R. Bose, M. Verheij, A. Haimovitz-Friedman, K. Scotto, Z.
Fuks, R. Kolesnick, Cell 82 (1995) 405^414.
[15] J.P. Ja¡re¤zou, T. Levade, A. Bettaieb, N. Andrieu, C. Be-
zombes, N. Maestre, S. Vermeersch, A. Rousse, G. Laurent,
EMBO J. 15 (1996) 2417^2424.
[16] E. Wang, W.P. Norred, C.W. Bacon, R.T. Riley, A.H. Mer-
rill Jr., J. Biol. Chem. 266 (1991) 14486^14490.
[17] N. Mano, Y. Oda, K. Yamada, N. Asakawa, K. Katayama,
Anal. Biochem. 244 (1997) 291^300.
[18] S.A. Hill, S.G. Shaughnessy, P. Joshua, J. Ribau, R.C. Aus-
tin, T.J. Podor, Blood 87 (1996) 5061^5073.
[19] G. Powis, in: G. Powis, R.A. Prough (Eds.), Metabolism
and Action of Anti-cancer Drugs, Taylor and Francis, Lon-
don, 1987, pp. 211^246.
[20] T. Levade, J.-P. Ja¡re¤zou, Biochim. Biophys. Acta 1438
(1999) 1^17.
[21] K. Hofmann, V.M. Dixit, Trends Biol. Sci. 23 (1998) 374^
377.
[22] S.L. Schissel, G.A. Keesler, E.H. Schuchman, K.J. Williams,
I. Tabas, J. Biol. Chem. 273 (1998) 18250^18259.
[23] B. Segui, C. Bezombes, E. Uro-Coste, J.A. Medin, N. An-
drieu-Abadie, N. Auge, A. Brouchet, G. Laurent, R. Sal-
vayre, J.-P. Ja¡re¤zou, T. Levade, FASEB J. 14 (2000) 36^47.
[24] J.A. Foekens, M. Schmitt, W.L. van Putten, H.A. Peters,
M.D. Kramer, F. Janicke, J.G. Klijn, J. Clin. Oncol. 12
(1993) 1648^1658.
[25] H. Pedersen, J. Grondahl-Hansen, D. Francis, K. Osterlind,
H.H. Hansen, K. Dano, N. Brunner, Cancer Res. 54 (1994)
120^123.
[26] Y. Sugiura, L. Ma, B. Sun, H. Shimada, W.E. Laug, R.C.
Seeger, Y. DeClerck, Cancer Res. 59 (1999) 1327^1336.
[27] H.C. Kwaan, J. Wang, K. Svoboda, P.J. Declerck, Br. J.
Cancer 82 (2000) 1702^1708.
BBAMCR 14732 17-4-01
S. Soeda et al. / Biochimica et Biophysica Acta 1538 (2001) 234^241 241
